Abatacept Reduces Levels of Switched Memory B Cells, Autoantibodies, and Immunoglobulins in Patients with Rheumatoid Arthritis

201472 citationsJournal Articlebronze Open Access

Authors

Mirko Scarsi · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Lucia Paolini

Doris Ricotta · Bristol-Myers Squibb (Italy)

Antonio Pedrini · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Silvia Piantoni · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Luigi Caimi · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Anǵela Tincani

Abstract

ABA treatment in patients with RA can reduce signs of polyclonal B cell activation, inducing a trend toward normalization of serum levels of different classes of Ig and of FLC, decreasing titers of ACPA and RF, and percentages of post-switch memory B cells.

Topics & Keywords

Monoclonal and Polyclonal Antibodies Research T-cell and B-cell Immunology Systemic Lupus Erythematosus Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The Journal of Rheumatology

Volume 41, Issue 4, pp. 666-672

DOI: 10.3899/jrheum.130905

Field-Weighted Citation Impact: 7.23